ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,912Medicare Part D Prescriptions Filled, Including Refills

Rank: 98 out of 1802

$494K Total Retail Price of All Prescriptions

Rank: 97 out of 1802

464 Patients Receiving at Least One Drug in Part D
78%Patients 65 Years and Older
48% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Wisconsin
Lower avg

Schedule Two
Controlled Substances

11% of this provider’s 464 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

11% of this provider’s 464 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

1% of this provider’s 7,392 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$55 was the average price of a prescription from this provider, compared to $54 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Wisconsin
SIMVASTATIN 353 318 1 1
HYDROCHLOROTHIAZIDE 326 290 2 8
LISINOPRIL 286 244 3 3
FUROSEMIDE 263 234 4 5
LEVOTHYROXINE SODIUM 254 231 5 2
OMEPRAZOLE 233 187 6 4
METFORMIN HCL 220 188 7 11
METOPROLOL SUCCINATE 214 190 8 13
POTASSIUM CHLORIDE 169 144 9 15
METOPROLOL TARTRATE 161 142 10 9
WARFARIN SODIUM 147 113 11 7
GABAPENTIN 142 111 12 16
ADVAIR DISKUS 139 112 13 32
ALLOPURINOL 130 122 14 24
TRAMADOL HCL 129 113 15 22
ATORVASTATIN CALCIUM 124 101 16 14
HYDROCODONE-ACETAMINOPHEN 124 61 S3 16 10
TAMSULOSIN HCL 108 97 18 28
AMLODIPINE BESYLATE 105 91 19 6
ZOLPIDEM TARTRATE 104 85 20 27
CITALOPRAM HBR 101 77 21 17
ATENOLOL 89 80 22 12
LOVASTATIN 87 52 23 25
DONEPEZIL HCL 86 86 24 26
LOSARTAN POTASSIUM 85 83 25 18
FLUOXETINE HCL 77 74 26 35
ROPINIROLE HCL 77 77 26 89
RANITIDINE HCL 77 65 26 30
CYMBALTA 75 45 29 75
CLOPIDOGREL 73 64 30 48
FLUTICASONE PROPIONATE 72 60 31 37
SPIRONOLACTONE 69 64 32 53
PREDNISONE 68 61 33 33
GLIMEPIRIDE 66 38 34 42
CRESTOR 64 56 35 31
CARVEDILOL 61 61 36 36
GEMFIBROZIL 59 43 37 83
NEXIUM 56 27 38 50
DOXAZOSIN MESYLATE 56 56 38 62
LEVOFLOXACIN 55 39 40 154
PLAVIX 55 43 40 81
SPIRIVA 53 53 42 72
NAMENDA 53 53 42 34
DIOVAN 53 41 42 57
DIGOXIN 53 53 42 45
PANTOPRAZOLE SODIUM 52 49 46 44
ENALAPRIL MALEATE 52 51 46 40
ALENDRONATE SODIUM 52 29 46 21
DIVALPROEX SODIUM 51 51 49 74
PRAVASTATIN SODIUM 51 51 49 19
LANTUS 50 50 51 47
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 23, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.